On August 27th, 2018 MS Money Moves initiated coverage on Adamis Pharmaceuticals (ADMP). At the time it was trading at $2.85 per share. Our analysis of the company indicated that it was oversold and undervalued on the heels of a public offering of 11,666,667 shares of common stock at $3.0 per share which raised around $35,000,000. Part 1 of our thesis was that ADMP was set to rebound leading into their PDUFA date on September 27th for SYMJEPI .15mg, a prefilled epinephrine syringe. Looking back after today part one was validated. At the markets . . .